Implementation of pharmacogenomics in product information
Aim: The aim of our study was to analyse the level of implementation of pharmacogenomics (PGx) in product information (PI) of medicinal products approved through national procedures in the EU. Materials & methods: In the analysis, we included nationally approved medicinal products in Croatia if guidelines for relevant substances were published. Results: Overall, 265 marketing authorizations were analyzed. The majority of data included in PI was only informative, while the most frequent PGx biomarkers were genes which code CYP P450. Analysis according to the Anatomical Therapeutic Chemical classification revealed that most substances belonged to the nervous system. Conclusion: Although hindrances in implementation are anticipated, PI should be more specific in terms of when the testing is indicated and should include actionable recommendations according to the results of PGx testing.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 21(2020), 7 vom: 17. Mai, Seite 443-448 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Skvrce, Nikica Mirošević [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Implementation |
|---|
| Anmerkungen: |
Date Completed 19.04.2021 Date Revised 19.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2019-0166 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309203031 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309203031 | ||
| 003 | DE-627 | ||
| 005 | 20231225133408.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2019-0166 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1030.xml |
| 035 | |a (DE-627)NLM309203031 | ||
| 035 | |a (NLM)32336208 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Skvrce, Nikica Mirošević |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Implementation of pharmacogenomics in product information |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2021 | ||
| 500 | |a Date Revised 19.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: The aim of our study was to analyse the level of implementation of pharmacogenomics (PGx) in product information (PI) of medicinal products approved through national procedures in the EU. Materials & methods: In the analysis, we included nationally approved medicinal products in Croatia if guidelines for relevant substances were published. Results: Overall, 265 marketing authorizations were analyzed. The majority of data included in PI was only informative, while the most frequent PGx biomarkers were genes which code CYP P450. Analysis according to the Anatomical Therapeutic Chemical classification revealed that most substances belonged to the nervous system. Conclusion: Although hindrances in implementation are anticipated, PI should be more specific in terms of when the testing is indicated and should include actionable recommendations according to the results of PGx testing | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a implementation | |
| 650 | 4 | |a pharmacogenomics | |
| 650 | 4 | |a product information | |
| 700 | 1 | |a Krivokapić, Sonja |e verfasserin |4 aut | |
| 700 | 1 | |a Božina, Nada |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 21(2020), 7 vom: 17. Mai, Seite 443-448 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g number:7 |g day:17 |g month:05 |g pages:443-448 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2019-0166 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2020 |e 7 |b 17 |c 05 |h 443-448 | ||